Publicaciones en colaboración con investigadores/as de Uppsala University Hospital (45)

2023

  1. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae

    American Journal of Transplantation, Vol. 23, Núm. 7, pp. 1022-1034

  2. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial

    European Journal of Heart Failure, Vol. 25, Núm. 11, pp. 2007-2017

  3. The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

    American Journal of Hematology, Vol. 98, Núm. 12, pp. 1856-1868

2022

  1. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT

    Bone Marrow Transplantation, Vol. 57, Núm. 5, pp. 817-823

  2. Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors

    Neuroendocrinology, Vol. 112, Núm. 12, pp. 1155-1167

2021

  1. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

    Leukemia, Vol. 35, Núm. 12, pp. 3444-3454

  2. Correction to: Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS (Intensive Care Medicine, (2020), 46, 12, (2200-2211), 10.1007/s00134-020-06192-2)

    Intensive Care Medicine

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS

    Intensive Care Medicine, Vol. 46, Núm. 12, pp. 2200-2211

2019

  1. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: A joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)

    Europace, Vol. 21, Núm. 2, pp. 192-193

  2. Diagnosis of acute myocardial infarction in the presence of left bundle branch block

    Heart, Vol. 105, Núm. 20, pp. 1559-1567

  3. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 3, pp. 522-528

  4. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study

    Clinical Cardiology, Vol. 42, Núm. 5, pp. 498-505

  5. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period

    ESC Heart Failure, Vol. 6, Núm. 1, pp. 174-181

  6. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

    The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180

  7. Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

    Neuroendocrinology

2018

  1. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

    The Lancet Oncology, Vol. 19, Núm. 6, pp. 747-757

  2. Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: Viewpoint of the task force

    European Heart Journal

2017

  1. Carbohydrates and insulin resistance in clinical nutrition: Recommendations from the ESPEN expert group

    Clinical Nutrition, Vol. 36, Núm. 2, pp. 355-363

  2. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial

    The Lancet, Vol. 389, Núm. 10081, pp. 1799-1808